Activin A in the Regulation of Corneal Neovascularization and Vascular Endothelial Growth Factor Expression

American Journal of Pathology

Volumn 164, Issue 4, 2004, Pages 1293-1302

  Poulaki, Vassiliki ^a   Mitsiades, Nicholas ^a   Kruse, Friedrich E ^b   Radetzky, Sven ^c   Iliaki, Eirini ^a   Kirchhof, Bernd ^c   Joussen, Antonia M ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN A; GLYCOPROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; RECOMBINANT PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; CORNEA EPITHELIUM; CORNEA NEOVASCULARIZATION; ENZYME ACTIVITY; EPITHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN SECRETION;

EID: 1642393251     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)63216-6     Document Type: Article

References (58)

1. Danesi R, Agen C, Benelli U, Paolo AD, Nardini D, Bocci G, Basolo F, Campagni A, Tacca MD: Inhibition of experimental angiogenesis by the somatostatin analogue octreotide acetate (SMS 201-995). Clin Cancer Res 1997, 3:265-272
2. Fotsis T, Pepper M, Adlercreutz H, Fleischmann G, Hase T, Montesano R, Schweigerer L: Genistein, a dietary-derived inhibitor of in vitro angiogenesis. Proc Natl Acad Sci USA 1993, 90:2690-2694
3. Joussen AM, Kruse FE, Volcker HE, Kirchhof B: Topical application of methotrexate for inhibition of corneal angiogenesis. Graefes Arch Clin Exp Ophthalmol 1999, 237:920-927
4. Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC, Abraham JA: The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 1991, 266:11947-11954
5. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF: Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983, 219:983-985
6. Ferrara N, Houck K, Jakeman L, Leung DW: Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev 1992, 13:18-32
7. Moromizato Y, Stechschulte S, Miyamoto K, Murata T, Tsujikawa A, Joussen AM, Adamis AP: CD18 and ICAM-1-dependent corneal neovascularization and inflammation after limbal injury. Am J Pathol 2000, 157:1277-1281
8. Amano S, Rohan R, Kuroki M, Tolentino M, Adamis AP: Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization. Invest Ophthalmol Vis Sci 1998, 39:18-22
9. Vale W, Rivier C, Hsueh A, Campen C, Meunier H, Bicsak T, Vaughan J, Corrigan A, Bardin W, Sawchenko P, et al: Chemical and biological characterization of the inhibin family of protein hormones. Recent Prog Horm Res 1988, 44:1-34
10. Mather JP, Moore A, Li RH: Activins, inhibins, and follistatins: further thoughts on a growing family of regulators. Proc Soc Exp Biol Med 1997, 215:209-222
11. Attisano L, Wrana JL, Cheifetz S, Massague J: Novel activin receptors: distinct genes and alternative mRNA splicing generate a repertoire of serine/threonine kinase receptors. Cell 1992, 68:97-108
12. Massague J, Andres J, Attisano L, Cheifetz S, Lopez-Casillas F, Ohtsuki M, Wrana JL: TGF-beta receptors. Mol Reprod Dev 1992, 32:99-104
13. Attisano L, Wrana JL, Montalvo E, Massague J: Activation of signalling by the activin receptor complex. Mol Cell Biol 1996, 16:1066-1073
14. Mathews LS, Vale WW: Expression cloning of an activin receptor, a predicted transmembrane serine kinase. Cell 1991, 65:973-982
15. ten Dijke P, Yamashita H, Ichijo H, Franzen P, Laiho M, Miyazono K, Heldin CH: Characterization of type I receptors for transforming growth factor-beta and activin. Science 1994, 264:101-104
16. Kretzschmar M, Massague J: SMADs: mediators and regulators of TGF-beta signaling. Curr Opin Genet Dev 1998, 8:103-111
17. Eto Y, Tsuji T, Takezawa M, Takano S, Yokogawa Y, Shibai H: Purification and characterization of erythroid differentiation factor (EDF) isolated from human leukemia cell line THP-1. Biochem Biophys Res Commun 1987, 142:1095-1103
18. Murata M, Onomichi K, Eto Y, Shibai H, Muramatsu M: Expression of erythroid differentiation factor (EDF) in Chinese hamster ovary cells. Biochem Biophys Res Commun 1988, 151:230-235
19. Shiozaki M, Kosaka M, Eto Y: Activin A: a commitment factor in erythroid differentiation. Biochem Biophys Res Commun 1998, 242:631-635
20. Mather JP, Woodruff TK, Krummen LA: Paracrine regulation of reproductive function by inhibin and activin. Proc Soc Exp Biol Med 1992, 201:1-15
21. Gurdon JB, Harger P, Mitchell A, Lemaire P: Activin signalling and response to a morphogen gradient. Nature 1994, 371:487-492
22. Vale W, Rivier J, Vaughan J, McClintock R, Corrigan A, Woo W, Karr D, Spiess J: Purification and characterization of an FSH releasing protein from porcine ovarian follicular fluid. Nature 1986, 321:776-779
23. Jaffe GJ, Harrison CE, Lui GM, Roberts WL, Goldsmith PC, Mesiano S, Jaffe RB: Activin expression by cultured human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci 1994, 35:2924-2931
24. Yamamoto T, Takeuchi S, Suzuki K, Yamashita H: Expression and possible roles of activin A in proliferative vitreoretinal diseases. Jpn J Ophthalmol 2000, 44:221-226
25. You L, Kruse FE: Differential effect of activin A and BMP-7 on myofibroblast differentiation and the role of the Smad signaling pathway. Invest Ophthalmol Vis Sci 2002, 43:72-81
26. Poulaki V, Qin W, Joussen AM, Hurlbut P, Wiegand SJ, Rudge J, Yancopoulos GD, Adamis AP: Acute intensive insulin therapy exacerbates diabetic blood-retinal barrier breakdown via hypoxia-inducible factor-lalpha and VEGF. J Clin Invest 2002, 109:805-815
27. Joussen AM, Beecken WD, Moromizato Y, Schwartz A, Kirchhof B, Poulaki V: Inhibition of inflammatory corneal angiogenesis by TNP-470. Invest Ophthalmol Vis Sci 2001, 42:2510-2516
28. Saita N, Fujiwara N, Yano I, Soejima K, Kobayashi K: Trehalose 6,6'-dimycolate (cord factor) of Mycobacterium tuberculosis induces corneal angiogenesis in rats. Infect Immun 2000, 68:5991-5997
29. Frater-Schroder M, Risau W, Hallmann R, Gautschi P, Bohlen P: Tumor necrosis factor type alpha, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo. Proc Natl Acad Sci USA 1987, 84:5277-5281
30. Henricson BE, Benjamin WR, Vogel SN: Differential cytokine induction by doses of lipopolysaccharide and monophosphoryl lipid A that result in equivalent early endotoxin tolerance. Infect Immun 1990, 58:2429-2437
31. Yoshida S, Ono M, Shono T, Izumi H, Ishibashi T, Suzuki H, Kuwano M: Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis. Mol Cell Biol 1997, 17:4015-4023
32. Liu WL, Guo X, Chen QQ, Guo ZG: VEGF protects bovine aortic endothelial cells from TNF-alpha- and H(2)O(2)-induced apoptosis via co-modulatory effects on p38-and p42/p44-CCDPK signaling. Acta Pharmacol Sin 2002, 23:45-49
33. Donnahoo KK, Shames BD, Harken AH, Meldrum DR: The role of tumor necrosis factor in renal ischemia-reperfusion injury. J Urol 1999, 162:196-203
34. Hubner G, Hu Q, Smola H, Werner S: Strong induction of activin expression after injury suggests an important role of activin in wound repair. Dev Biol 1996, 173:490-498
35. Seishima M, Nojiri M, Akiyama T, Noma A, Etoh Y, Kitajima Y: Expression of activin A in human keratinocytes at early stages of cultivation. FEBS Lett 1996, 398:120-124
36. Jones KL, Brauman JN, Groome NP, de Kretser DM, Phillips DJ: Activin A release into the circulation is an early event in systemic inflammation and precedes the release of follistatin. Endocrinology 2000, 141:1905-1908
37. Phillips DJ, Jones KL, Scheerlinck JY, Hedger MP, de Kretser DM: Evidence for activin A and follistatin involvement in the systemic inflammatory response. Mol Cell Endocrinol 2001, 180:155-162
38. Massague J, Chen YG: Controlling TGF-beta signaling. Genes Dev 2000, 14:627-644
39. Cocolakis E, Lemay S, All S, Lebrun JJ: The p38 MAPK pathway is required for cell growth inhibition of human breast cancer cells in response to activin. J Biol Chem 2001, 276:18430-18436
40. Fuller K, Bayley KE, Chambers TJ: Activin A is an essential cofactor for osteoclast induction. Biochem Biophys Res Commun 2000, 268:2-7
41. Raingeaud J, Gupta S, Rogers JS, Dickens M, Han J, Ulevitch RJ, Davis RJ: Pro-inflammatory cytokines and environmental stress cause p38 mitogen-activated protein kinase activation by dual phosphorylation on tyrosine and threonine. J Biol Chem 1995, 270:7420-7426
42. Sano Y, Harada J, Tashiro S, Gotoh-Mandeville R, Maekawa T, Ishii S: ATF-2 is a common nuclear target of Smad and TAK1 pathways in transforming growth factor-beta signaling. J Biol Chem 1999, 274:8949-8957
43. Hanafusa H, Ninomiya-Tsuji J, Masuyama N, Nishita M, Fujisawa J, Shibuya H, Matsumoto K, Nishida E: Involvement of the p38 mitogen-activated protein kinase pathway in transforming growth factor-beta-induced gene expression. J Biol Chem 1999, 274:27161-27167
44. Yamaguchi K, Shirakabe K, Shibuya H, Irie K, Oishi I, Ueno N, Taniguchi T, Nishida E, Matsumoto K: Identification of a member of the MAPKKK family as a potential mediator of TGF-beta signal transduction. Science 1995, 270:2008-2011
45. Shibuya H, Yamaguchi K, Shirakabe K, Tonegawa A, Gotoh Y, Ueno N, Irie K, Nishida E, Matsumoto K: TAB1: an activator of the TAK1 MAPKKK in TGF-beta signal transduction. Science 1996, 272:1179-1182
46. Inman GJ, Nicolas FJ, Callahan JF, Harling JD, Gaster LM, Reith AD, Laping NJ, Hill CS: SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol 2002, 62:65-74
47. Tretter YP, Hertel M, Munz B, ten Bruggencate G, Werner S, Alzheimer C: Induction of activin A is essential for the neuroprotective action of basic fibroblast growth factor in vivo. Nat Med 2000, 6:812-815
48. de Caestecker MP, Parks WT, Frank CJ, Castagnino P, Bottaro DP, Roberts AB, Lechleider RJ: Smad2 transduces common signals from receptor serine-threonine and tyrosine kinases. Genes Dev 1998, 12:1587-1592
49. Nusing RM, Barsig J: Induction of prostanoid, nitric oxide, and cytokine formation in rat bone marrow derived macrophages by activin A. Br J Pharmacol 1999, 127:919-926
50. Joussen AM, Murata T, Tsujikawa A, Kirchhof B, Bursell SE, Adamis AP: Leukocyte-mediated endothelial cell injury and death in the diabetic retina. Am J Pathol 2001, 158:147-152
51. McCarthy SA, Bicknell R: Inhibition of vascular endothelial cell growth by activin-A. J Biol Chem 1993, 268:23066-23071
52. Breit S, Ashman K, Wilting J, Rossler J, Hatzi E, Fotsis T, Schweigerer L: The N-myc oncogene in human neuroblastoma cells: down-regulation of an angiogenesis inhibitor identified as activin A. Cancer Res 2000, 60:4596-4601
53. Plendl J: Angiogenesis and vascular regression in the ovary. Anat Histol Embryol 2000, 29:257-266
54. Yamashita H, Shimizu A, Kato M, Nishitoh H, Ichijo H, Hanyu A, Morita I, Kimura M, Makishima F, Miyazono K: Growth/differentiation factor-5 induces angiogenesis in vivo. Exp Cell Res 1997, 235:218-226
55. Woodruff TK: Regulation of cellular and system function by activin. Biochem Pharmacol 1998, 55:953-963
56. Hubner G, Brauchle M, Gregor M, Werner S: Activin A: a novel player and inflammatory marker in inflammatory bowel disease? Lab Invest 1997, 77:311-318
57. Yu EW, Dolter KE, Shao LE, Yu J: Suppression of IL-6 biological activities by activin A and implications for inflammatory arthropathies. Clin Exp Immunol 1998, 112:126-132
58. Letterio JJ, Roberts AB: Regulation of immune responses by TGF-beta. Annu Rev Immunol 1998, 16:137-161